secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2021-11-19T23:59:59+00:00
Accession:  0001564590-21-057696
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics appoints two new directors and lead independent director
-----------------------------------------------------------------------------

- Director Peter Moldt resigned from Board and Compensation Committee; no disagreement.
- Board expanded from 8 to 9; appointed Brian O'Callaghan and Frank Lee as Class I directors.
- O'Callaghan named chair of Compensation Committee; Lee joins Nominating and Corporate Governance Committee.
- Each new director received initial option for 27,860 shares, annual option for 13,930 shares, and cash retainers.
- Existing director Jim Healy appointed as lead independent director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/bolt-8k_20211115.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-057696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer